Prescient Therapeutics Ltd
ASX:PTX
Prescient Therapeutics Ltd
Research & Development
Prescient Therapeutics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Research & Development
-AU$6.7m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-18%
|
|
|
Immutep Ltd
ASX:IMM
|
Research & Development
-AU$61.4m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-21%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$34.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Prescient Therapeutics Ltd
Glance View
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
See Also
What is Prescient Therapeutics Ltd's Research & Development?
Research & Development
-6.7m
AUD
Based on the financial report for Jun 30, 2025, Prescient Therapeutics Ltd's Research & Development amounts to -6.7m AUD.
What is Prescient Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-18%
Over the last year, the Research & Development growth was 4%. The average annual Research & Development growth rates for Prescient Therapeutics Ltd have been -25% over the past three years , -19% over the past five years , and -18% over the past ten years .
